Since May 2018, Jeff has been Founder and CEO of BAIT, a new company utilizing synthetic biology to develop innovative cell-based therapeutics for autoimmune and inflammatory diseases.
Prior to this, Jeff was co-Founder and CSO at Delinia; Vice President of Research at aTyr Pharma; and Executive Director for Stem Cell Sciences at Exelixis. Jeff also worked at Bayer Biotechnology for 13 years, where he was responsible for therapeutic protein discovery, establishing protein engineering and therapeutic antibody technology platforms and led a program that advanced into clinical development for multiple disease indications.
Jeff holds a BA in Biology from John Hopkins University and a PhD in Molecular Biology from Washington University in St Louis. Jeff continued his training in the lab of Dr. Paul Wassarman at Harvard Medical School and at the Roche Institute of Molecular Biology.